Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease

Documenti analoghi

• Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease
  di: Diana L. Price, et al.
  Pubblicazione: (2024-03-01)
• Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease
  di: Michel Alexander Steiner
  Pubblicazione: (2024-03-01)
• The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease
  di: Diana L. Price, et al.
  Pubblicazione: (2018-11-01)
• Effect of spermidine on misfolding and interactions of alpha-synuclein.
  di: Alexey V Krasnoslobodtsev, et al.
  Pubblicazione: (2012-01-01)
• Rational design of structure‐based vaccines targeting misfolded alpha‐synuclein conformers of Parkinson's disease and related disorders
  di: Jose Miguel Flores‐Fernandez, et al.
  Pubblicazione: (2024-07-01)